Hence, the BEACON CRC trial combined encorafenib, cetuximab, and binimetinib and demonstrated that the combination was clinically efficacious, extended OS, and improved responses in patients with metastatic colorectal cancer and BRAF V600E mutations. This evidence concerns the gene BRAF and metastatic colorectal cancer.